# A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamata

Source: https://onco.cc/trials/nct04590326/  
OnCo record `nct04590326` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Cemiplimab in ovarian cancer and endometrial cancer, run by Regeneron Pharmaceuticals, now recruiting.

## Summary

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab is a phase 1/2 interventional study registered as NCT04590326 by Regeneron Pharmaceuticals, with 612 participants planned, started 2020-12-08 and due to reach its primary completion in 2027-03-25. Interventions recorded: REGN5668, Cemiplimab, Ubamatamab, Sarilumab, Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]. Conditions listed: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04590326
- Phase: 1/2
- Setting: A Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific Antibody) Administered in Combination With Other Agents in MUC16 + Malignancies
- Sponsor: Regeneron Pharmaceuticals
- Enrolled: 612

## Sources

- ClinicalTrials.gov NCT04590326: https://clinicaltrials.gov/study/NCT04590326

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Cemiplimab](https://onco.cc/drugs/cemiplimab/), [Ubamatamab](https://onco.cc/drugs/ubamatamab/)
- companies: [Regeneron](https://onco.cc/companies/regeneron/)

---
JSON: https://onco.cc/api/v1/entities/nct04590326.json